Navigation Links
Lawson scientist presents joint pain treatment 2.0
Date:8/12/2011

LONDON, ON Osteoarthritis (OA) is the most common form of arthritis, affecting roughly 10% of Canadians. This degradation of the joints is painful and crippling, especially when it affects the knee. Although there are viable OA treatment options, they are short-lived and can have serious side-effects. According to Lawson Health Research Institute's Dr. Robert Petrella, principal investigator in the COR1.0 study, the next generation of OA treatment has arrived.

When patients have OA in the knee, the fluid in their joint breaks down, causing pain and preventing natural shock absorption. To treat this condition, gel-like substances called "viscosupplements" are injected into the knee. This acts as a supplement for the fluid loss and provides temporary pain relief. In the COR1.0 study, Dr. Petrella and his colleagues compared Synvisc-One, the leading market viscosupplement for OA in the knee, to Hydros-TA Joint Therapy. Hydros-TA is a unique dual-action treatment combining steroids within a viscosupplement. It is believed to provide faster acting, longer lasting pain relief than either treatment alone.

To compare and evaluate the safety and effectiveness of both treatments, Dr. Petrella and his team conducted a double-blinded, multi-center clinical trial. Across eight sites in Canada, Belgium, and The Netherlands, a total of 98 patients were given a single injection and then monitored for six months. Results show trends suggesting Hydros-TA provides superior pain relief and improved function, causes fewer adverse events, and has a higher overall response rate. For patients, this could mean greater, more consistent pain relief with faster onset.

"Patients are really searching for better options for osteoarthritis therapy," Dr. Petrella explains. "Hydros-TA takes effect very quickly and lasts longer than other available therapies, allowing patients to achieve and sustain a higher quality of life."

Dr. Petrella and Carbylan BioSurgery Inc., the makers of Hydros-TA, are planning a larger multi-center trial to take place in the United States next year.


'/>"/>

Contact: Sonya Gilpin
sonya.gilpin@lawsonresearch.com
519-685-8500 x75852
Lawson Health Research Institute
Source:Eurekalert

Related medicine news :

1. Scientists explore the intersection of health, society and microbial ecology
2. Scientists explain unique activity of TB drug pyrazinamide
3. BIDMC scientists receive Challenge Awards from Prostate Cancer Foundation
4. USC scientist develops virus that targets HIV
5. Scientists Take Navel-Gazing to New Level
6. Johns Hopkins scientists map genes for common form of brain cancer
7. Scientists May Have Found Missing Link to Common Brain Cancer
8. Have we met before? Scientists show why the brain has the answer
9. Scientists Warn of New Multidrug-Resistant Salmonella
10. Johns Hopkins scientists begin first-of-its-kind research to create blood platelets from stem cells
11. Scientists show swamp gas protects blood vessels from complications of diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, ... enlisted New York City-based sports and entertainment marketing firm Leverage Agency as its ... for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Youth Futures ... great success and feedback from high school and college students who have participated in ... held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sports Brand ... brace, which retails normally at $29.97; for the remaining days of March, the ... also been reduced to a special price of just $10 (regular retail price $19.97). ...
(Date:3/29/2017)... Louisiana (PRWEB) , ... March 29, 2017 , ... ... in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of ... Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the counter ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)...  Maxor National Pharmacy Services, LLC ("Maxor"), a leading ... Leah Bailey as General Counsel.  Bailey will serve ... With more than 13 years of experience ... on health care, Bailey joins the Maxor team coming ... advised the PBM, Specialty, and Mail Order business areas ...
(Date:3/29/2017)... , March 29, 2017 Varian Medical Systems ... report results for the second quarter of fiscal year 2017 ... 2017.  The news release will be followed by a teleconference ... news release and a link to the conference call webcast ... .  To access the teleconference call and replay: ...
Breaking Medicine Technology: